$LIMN SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Regulation FD Disclosure FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.
18 Aug 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Material Modification to Rights of Security Holders +2 more
14 Aug 2026	10-Q
04 Aug 2026	8-K: Submission of Matters to a Vote of Security Holders
30 Jul 2026	8-K: Other Events
24 Jul 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
22 Jul 2026	SCHEDULE 13G
14 Jul 2026	Form 4: Valetudo Therapeutics Llc, 10% owner and 1 other Acquired 3,448,926 shares (Other Transaction)
14 Jul 2026	SCHEDULE 13D/A
13 Jul 2026	Proxy statement: annual meeting on August 3, 2026
06 Jul 2026	Form 4: Valetudo Therapeutics Llc, 10% owner and 1 other Disposed of 4,373,603 shares (Other Transaction)
06 Jul 2026	Form 3: Ewon Comfortech Co., Ltd., 10% owner Holds 5,500,000 shares of Common Stock, par value $0.0001 per share
06 Jul 2026	SCHEDULE 13G/A
06 Jul 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
30 Jun 2026	PRE 14A
24 Jun 2026	S-1
18 Jun 2026	D
03 Jun 2026	424B3
03 Jun 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
27 May 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Comments